Atlas Trials

The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

Clinical trial NCT05369364 · UNKNOWN

Trial details

NCT number
NCT05369364
Sponsor
Peking University People's Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Immune Thrombocytopenia
Start date
2022-06-01
Primary completion
2025-12-30
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.